Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedApr 03, 2026
DataAggregated Company Financials
Companies41
  • 7D3.8%
  • 3M12.3%
  • 1Y32.0%
  • YTDn/a

In the last week, the Pharma industry is up 3.9%, with Chugai Pharmaceutical up 8.8%. In the last 12 months, the industry was up 33%. As for the next few years, earnings are expected to grow by 8.6% per annum.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Apr 2026JP¥51.5tJP¥17.3tJP¥2.2t16.5x23.6x3x
Sun, 01 Mar 2026JP¥54.2tJP¥17.3tJP¥2.2t16x24.9x3.1x
Tue, 27 Jan 2026JP¥47.7tJP¥16.9tJP¥1.9t16.5x25x2.8x
Thu, 25 Dec 2025JP¥46.1tJP¥16.9tJP¥1.9t16.4x24.2x2.7x
Sat, 22 Nov 2025JP¥45.5tJP¥16.9tJP¥1.9t15.6x23.9x2.7x
Mon, 20 Oct 2025JP¥41.2tJP¥16.8tJP¥1.8t15x22.5x2.5x
Wed, 17 Sep 2025JP¥41.5tJP¥16.8tJP¥1.8t16.1x22.7x2.5x
Fri, 15 Aug 2025JP¥39.8tJP¥16.8tJP¥1.8t16.3x21.7x2.4x
Sun, 13 Jul 2025JP¥38.9tJP¥16.8tJP¥1.8t15.1x22.2x2.3x
Tue, 10 Jun 2025JP¥41.0tJP¥16.8tJP¥1.8t14.5x23.2x2.4x
Thu, 08 May 2025JP¥41.9tJP¥16.7tJP¥1.7t14.9x24.8x2.5x
Sat, 05 Apr 2025JP¥39.3tJP¥16.5tJP¥1.5t14.3x26.1x2.4x
Mon, 03 Mar 2025JP¥40.4tJP¥16.5tJP¥1.5t15.5x26.9x2.5x
Wed, 29 Jan 2025JP¥41.2tJP¥16.1tJP¥1.4t16x29.3x2.6x
Fri, 27 Dec 2024JP¥41.9tJP¥16.1tJP¥1.4t15.9x29.7x2.6x
Sun, 24 Nov 2024JP¥41.4tJP¥16.1tJP¥1.4t15x29.3x2.6x
Tue, 22 Oct 2024JP¥44.9tJP¥15.6tJP¥1.2t15.9x37.3x2.9x
Thu, 19 Sep 2024JP¥43.7tJP¥15.5tJP¥1.2t17.6x36.3x2.8x
Sat, 17 Aug 2024JP¥46.6tJP¥15.5tJP¥1.2t17.1x38.8x3x
Mon, 15 Jul 2024JP¥45.4tJP¥15.0tJP¥1.1t19.1x41.4x3x
Wed, 12 Jun 2024JP¥41.5tJP¥15.0tJP¥1.1t17.9x37.9x2.8x
Fri, 10 May 2024JP¥40.4tJP¥14.9tJP¥1.3t18.6x32.3x2.7x
Sun, 07 Apr 2024JP¥41.0tJP¥15.1tJP¥1.2t19.2x33.7x2.7x
Tue, 05 Mar 2024JP¥43.5tJP¥15.1tJP¥1.2t19.9x35.8x2.9x
Thu, 01 Feb 2024JP¥40.9tJP¥15.2tJP¥1.4t20.6x29.8x2.7x
Sat, 30 Dec 2023JP¥38.8tJP¥15.2tJP¥1.4t19.5x28.2x2.6x
Mon, 27 Nov 2023JP¥39.7tJP¥15.2tJP¥1.4t20.2x28.9x2.6x
Wed, 25 Oct 2023JP¥38.6tJP¥14.9tJP¥1.4t23.5x27x2.6x
Fri, 22 Sep 2023JP¥39.8tJP¥14.9tJP¥1.4t24.5x27.9x2.7x
Sun, 20 Aug 2023JP¥39.6tJP¥14.9tJP¥1.4t22.3x27.7x2.7x
Tue, 18 Jul 2023JP¥37.3tJP¥14.6tJP¥1.5t20x25.5x2.6x
Thu, 15 Jun 2023JP¥41.8tJP¥14.6tJP¥1.5t20.3x28.6x2.9x
Sat, 13 May 2023JP¥38.5tJP¥14.5tJP¥1.4t18.6x26.8x2.7x
Mon, 10 Apr 2023JP¥36.9tJP¥14.3tJP¥1.5t17x25.1x2.6x
Price to Earnings Ratio

25.1x


Total Market Cap: JP¥36.9tTotal Earnings: JP¥1.5tTotal Revenue: JP¥14.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 23.7x which is lower than its 3-year average PE of 28.6x.
  • The 3-year average PS ratio of 2.7x is lower than the industry's current PS ratio of 3.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 14% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Japanese Pharma compare with similar industries?

JP Market-0.87%
Healthcare2.77%
Pharma3.82%
Pharma3.82%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4519 Chugai PharmaceuticalJP¥9.20k8.8%
+JP¥1.2t		38.8%PE34.9x
4502 Takeda PharmaceuticalJP¥5.89k1.7%
+JP¥159.6b		29.7%PE82.4x
4578 Otsuka HoldingsJP¥11.32k2.1%
+JP¥121.4b		48.9%PE16.5x
4503 Astellas PharmaJP¥2.60k2.6%
+JP¥117.3b		89.1%PE14.4x
4151 Kyowa KirinJP¥2.63k6.8%
+JP¥87.9b		24.2%PE20.5x

Latest News

4502
JP¥5,890.00
Takeda Pharmaceutical
7D
1.7%
1Y
29.7%

Pipeline Progress And New Launches Will Secure Durable Long Term Earnings Power

Catalysts About Takeda Pharmaceutical Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty medicines across areas such as gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines. What are the underlying business or industry changes driving this perspective?
4553
JP¥4,160.00
Towa Pharmaceutical
7D
-0.6%
1Y
60.8%
4578
JP¥11,320.00
Otsuka Holdings
7D
2.1%
1Y
48.9%

4578: Future Repricing Will Rely On Morgan Stanley Upgrade Momentum

Analysts have fine tuned their view on Otsuka Holdings, trimming the price target slightly from about ¥14,603 to around ¥14,480. This reflects updated assumptions for revenue growth, profit margins and a modestly lower future P/E multiple following recent research commentary, including the Morgan Stanley upgrade rationale.
4534
JP¥3,580.00
Mochida Pharmaceutical
7D
-2.7%
1Y
15.5%
4523
JP¥5,032.00
Eisai
7D
2.2%
1Y
28.9%
4506
JP¥2,018.50
Sumitomo Pharma
7D
-0.6%
1Y
230.4%
4507
JP¥3,544.00
Shionogi
7D
2.5%
1Y
56.3%
4568
JP¥2,888.50
Daiichi Sankyo Company
7D
0.5%
1Y
-20.5%

4568: Oncology Pipeline Progress Will Drive Further Upside For Shares

Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).
4519
JP¥9,198.00
Chugai Pharmaceutical
7D
8.8%
1Y
38.8%

4519: Rich P/E And Clinical Setbacks Will Likely Restrain Future Upside

Analysts have nudged their price target for Chugai Pharmaceutical down from ¥6,584.94 to ¥6,400. This change reflects updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple.
4503
JP¥2,600.50
Astellas Pharma
7D
2.6%
1Y
89.1%
4540
JP¥3,831.00
Tsumura
7D
-0.3%
1Y
-8.7%
4887
JP¥2,237.00
Sawai Group Holdings
7D
-1.8%
1Y
15.3%
4586
JP¥80.00
MedRx
7D
-31.6%
1Y
17.6%
4151
JP¥2,631.50
Kyowa Kirin
7D
6.8%
1Y
24.2%
4890
JP¥301.00
Tsubota Laboratory
7D
-16.2%
1Y
-15.2%
4888
JP¥672.00
Stella Pharma
7D
-13.6%
1Y
93.1%